Cyclomics B.V.
Company Snapshot
Company Overview
Cyclomics, founded as a spinout from UMC Utrecht, is developing and commercializing liquid biopsy diagnostics for cancer care using proprietary ctDNA detection technology involving nanopore sequencing.
Cyclomic’s technology is called CyclomicsSeq; the technology is very sensitive, with even a single ctDNA molecule present in blood being detected and sequenced at close to 100% accuracy. The technology uses a combination of proprietary DNA adapters (backbones) and enzymes to capture ctDNA molecules and circularize them. This circular DNA is then amplified (via rolling circle amplification), creating long DNA concatemers, which are sequenced using long-read (nanopore) technology.
The company’s initial focus is on head and neck cancers (HNC), for which monitoring of treatment response and recurrence diseases is key to improving survival.
Company's Business Segments
- Sequencing Solutions : The company offers ultra-sensitive diagnostic tests for cancer detection and recurrence monitoring using a liquid biopsy method called CyclomicsSeq.
Applications/End User Industries
- Oncology
- Contract Research Organizations
- Life Sciences Research
- Life Sciences
- Hospitals
- Diagnostics
- Healthcare
- AI in Diagnostics
- AI in Cancer Diagnostics
- Diagnosis Center